In light of potential tariff threats from President Donald Trump, Pfizer Inc.’s (NYSE:PFE) CEO Albert Bourla has suggested the possibility of shifting the company’s overseas manufacturing to its U.S. facilities.
What Happened: At the TD Cowen healthcare conference, Bourla indicated that Pfizer, which already boasts an extensive U.S. manufacturing network, could relocate production to its domestic plants to avoid any potential tariffs, reported Reuters on Monday.
His remarks come as the pharmaceutical industry braces for a possible 25% tariff on imported goods. “We have the capabilities here (in the U.S.) and the manufacturing sites are operating in good capacity right now. If something happens, we will try to mitigate it by transferring from manufacturing sites outside to the manufacturing sites here,” Bourla said.
Pfizer has 10 manufacturing facilities and …
